He will start on July 7 and will take the reins of a company that has experienced recent flux.
BY RON SHINKMAN
David Stern, current chief executive officer of Boston IVF, has been named CEO of Kindbody, one of the largest chains of fertility clinics in the U.S. which has recently seen operational and management changes.
First official day in office: July 7
Stern is scheduled to begin work at the New York City-based Kindbody on July 7, according to a company spokesperson Margaret Ryan.
“David’s focus will be strengthening our operational infrastructure and investing in our team to drive Kindbody’s next chapter of growth and impact,” Ryan said in an email.
Through Ryan, Stern declined to comment until after he begins his new position. In a statement issued by Kindbody, he said he was “eager to build on the company’s strong foundation of clinical excellence by strengthening our operational infrastructure and investing in the exceptional team that will drive our next chapter of growth and impact.”
The hiring of Stern was a bit of a surprise to Robert Goodman, vice president of healthcare at MidCap Advisors, an advisory firm based in New York City. But he also believes it is a solid choice.
“Kindbody likely looked at him and said ‘he’s smart, he knows the business, and we’re retooling for a new future,’” he said.
Stern’s Tenure at Boston IVF
Stern took over the top reins at Boston IVF in January 2020. During that time, he has grown the business from five IVF labs to 11 and added clinics in Salt Lake City, Ohio and North Carolina, among other locations. Company revenue is now about $75 million a year, according to LeadIQ.
The privately-held Kindbody is significantly larger. It projected its 2023 revenue late in that year at approximately $180 million, and said its 2024 revenue could exceed more than $200 million.
However, the company has been buffeted in the past year-plus. It has shut or decided not to open six clinics since early 2024 – while opening three new ones – and has been trying to obtain an additional $75 million in financing.
Stern to return authority of “Office of the CEO” to role
The executive suite has also been in flux. Company founder Gina Bartasi rejoined Kindbody last June as its CEO, only to depart late last year. Prior to recruiting Stern, Kindbody had been run by an “Office of the CEO” comprised of three co-chief executives: President Gina Bruzzichesi, Chief Financial Officer Scott Bruckner, and Chief Business Officer Shilpa Patel.
Ryan said the Office of the CEO would be removed after Stern joins the company. She declined to discuss any other potential changes in the C-suite.
Boston IVF restructures under IVIRMA
Stern finished his tenure at Boston IVF after corporate restructuring a year and a half after IVIRMA’s acquisition of the firm. They quietly made known in February 2025 that Haryanto Hokianto would assume the role of Executive Director of Boston IVF, concurrently serving as Chief of Staff for IVI RMA North America.
Goodman believes Stern will focus first on stabilizing Kindbody, recruiting additional physicians, and then move on to growing the firm through mergers and acquisitions and other initiatives.
“He’s there to evaluate other opportunities – growth opportunities,” Goodman said.
